Your browser doesn't support javascript.
loading
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Armstrong, Andrew J; Nixon, Andrew B; Carmack, Andrea; Yang, Qian; Eisen, Tim; Stadler, Walter M; Jones, Robert J; Garcia, Jorge A; Vaishampayan, Ulka N; Picus, Joel; Hawkins, Robert E; Hainsworth, John D; Kollmannsberger, Christian K; Logan, Theodore F; Puzanov, Igor; Pickering, Lisa M; Ryan, Christopher W; Protheroe, Andrew; George, Daniel J; Halabi, Susan.
Afiliação
  • Armstrong AJ; Duke University Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina. andrew.armstrong@duke.edu.
  • Nixon AB; Duke University Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina.
  • Carmack A; Duke University Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina.
  • Yang Q; Duke University Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina.
  • Eisen T; University of Cambridge, Cambridge, United Kingdom.
  • Stadler WM; University of Chicago, Chicago, Illinois.
  • Jones RJ; University of Glasgow, The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
  • Garcia JA; Cleveland Clinic, Cleveland, Ohio.
  • Vaishampayan UN; University of Michigan/Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
  • Picus J; Washington University in St. Louis, St. Louis, Missouri.
  • Hawkins RE; Christie Cancer Research Centre, Manchester, United Kingdom.
  • Hainsworth JD; Sarah Cannon Research Institute, Nashville, Tennessee.
  • Kollmannsberger CK; BC Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada.
  • Logan TF; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.
  • Puzanov I; Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Pickering LM; Royal Marsden Hospital, London, United Kingdom.
  • Ryan CW; Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, Oregon.
  • Protheroe A; Department of Oncology, University of Oxford, Oxford, United Kingdom.
  • George DJ; Duke University Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina.
  • Halabi S; Department of Biostatistics, Duke University, Durham, North Carolina.
Clin Cancer Res ; 27(12): 3317-3328, 2021 06 15.
Article em En | MEDLINE | ID: mdl-33593885
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Antineoplásicos Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Antineoplásicos Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article